Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BMYBullishIndustry Newsnews

High materiality9/10

BMS Gains NDA Acceptance for Mezigdomide in RRMM; Potential 2027 FDA Decision

Jul 13, 2026, 7:02 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive NDA acceptance and strong Phase 3 data support upside; near-term catalyst with a 2027 PDUFA, though the actual approval remains years away and could be subject to risk.

AI summary

What happened, with direct paths to the underlying reporting

Bristol Myers Squibb announced that the FDA accepted an NDA for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) for relapsed or refractory multiple myeloma, with a PDUFA date of May 13, 2027. Phase 3 SUCCESSOR-2 showed a 52% reduction in progression risk (HR 0.48) and median PFS of 18.0 vs 8.3 months, underscoring momentum for BMS's CELMoD platform and potential long-term upside in RRMM.

FDA accepts NDA for mezigdomide with carfilzomib and dexamethasone in RRMM.
SUCCESSOR-2 shows PFS benefit; HR 0.48, 18.0 vs 8.3 months.
Two CELMoD programs for RRMM underpin BMS pipeline momentum.
Near-term NDA ruling date may drive share moves into 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

BMS Gains NDA Acceptance for Mezigdomide in RRMM; Potential 2027 FDA Decision

Appeals Court Revives $6.7B Celgene Shareholder Lawsuit Against BMS

BMS selects Houston for $2.3B multi-modal campus creating 500 jobs

BMY raises full-year guidance on Eliquis, Camzyos and Reblozyl momentum

Bristol-Myers Squibb poised for solid earnings, dividend appeal amid buzz